Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie has completed a clinical study titled ‘A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects With Moderate to Severe Atopic Dermatitis.’ The study aimed to evaluate the dosing flexibility of upadacitinib, an oral tablet, in treating moderate to severe atopic dermatitis (AD) in adults. This condition often requires systemic treatment beyond topical therapies. The study’s significance lies in its potential to improve treatment strategies for AD, a common inflammatory skin disease.
The intervention tested was upadacitinib, an approved drug for various inflammatory diseases, including AD. Participants received either 15 mg or 30 mg doses of upadacitinib orally once daily. The study assessed the drug’s effectiveness in reducing disease severity and improving patient outcomes.
The study was designed as an interventional trial with a randomized, sequential intervention model. It employed quadruple masking to ensure unbiased results, with the primary purpose of treatment. The study included a 12-week double-blind period followed by a 12-week single-blind period, with participants reassigned based on their response to treatment.
The study began on May 29, 2023, and was completed with the last update submitted on July 28, 2025. These dates mark the progression and completion of the trial, indicating the availability of results and insights into upadacitinib’s effectiveness.
The completion of this study could positively impact AbbVie’s stock performance and investor sentiment, as successful results may enhance the market position of upadacitinib in treating AD. This update places AbbVie in a competitive position within the pharmaceutical industry, particularly against companies developing similar treatments.
The study is now completed, and further details are available on the ClinicalTrials portal.